Stevanato Group

Stevanato Group has received market approval in Europe for liraglutide-based combination products that use its Alina pen injector platform. Approved configurations are Alina 30 for diabetes therapies and Alina 50 for weight management. Alina is a disposable pen with variable dosing (0.01–0.75 ml), provides visual, auditory and tactile feedback, and is compatible with 3-ml glass cartridges meeting ISO standards. Production takes place in Stevanato Group’s Drug Delivery Systems business unit. » More on de.investing.com

Stevanato Group reported Q1 2026 EPS of €0.11 and revenue of €273.6m, with EPS meeting guidance and revenue about 1.7% above forecasts. Growth was driven by the Biopharmaceutical and Diagnostic Solutions segment (+13%), while the Engineering segment shrank by 31%. Gross profit margin, operating margin and adjusted EBITDA improved, but higher tax rates weighed on net profitability. Despite the positive metrics, the shares fell about 4.05% in pre-market trading. » More on de.investing.com

Stevanato Group has filed with the U.S. securities regulator the notice for the annual general meeting on April 11, 2026, along with explanatory documents. The filing includes the 2025 sustainability report, the audit committee activity report, the report of the nomination and corporate governance committee, the 2025 remuneration report, a reasoned proposal from the audit committee and a slate of candidates for the board of directors. » More on de.investing.com